»Print   »Share   »Bookmark

All Cancers/Any Site

  • EAY131 (NCI-MATCH): Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
  • UW15068: UWCCC Precision Medicine Molecular Tumor Board Registry
  • Strata STR-001-001: An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations.
  • Exact Science 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

Breast Cancer


  • Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer : The ABC Trial
  • Alliance A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502
  • NRG BR-003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer


  • NSABP B-51/RTOG 1304: Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
  • SWOG S1418: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
  • UW16112: A Phase II Study of Neoadjuvant Weekly Carboplatin/Paclitaxel followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients with Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer

Metastatic/Advanced Disease:

  • ECOG EAI142: (18F) Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer
  • NRG-BR004: Paclitaxel, Trastuzumab and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer


  • Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Breast Screening Trials:

  • TMIST: Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Gastrointestinal Cancer


  • ECOG EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Biliary Tract:

  • SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel vs. Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers. 


  • A021502: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  • NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

  • NRG-GI004: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Genitourinary Cancer


  • ECOG-ACRIN EA8143: Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer


  • ECOG-ACRIN EA8143Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Rare Tumors:

  • Alliance A031702: Phase II Study of Cabozatinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors. 


  • City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
  • Genomic Medicine Institute - Cancer Specimen Banking: Molecular Mechanisms Involved in Cancer Predisposition
  • ECOG EAQ152 (COMET) - Communication and Education in Tumor Profiling. A Randomized Study of Pre-Disclosure Genetic Education vs. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling. 

Gynecological Cancer:

Ovarian/Fallopian Tube:

  • NRG-GY005: Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
  • NRG-GY016: A Phase II Study of MK-3475 (Pembrolizumab) + Epacodastat in Recurrent Clear Cell Carcinoma of the Ovary
  • University of Southern Alabama / MCI GON: A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus


  • NRG-GY014: Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer


Head and Neck:

  • NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with Contraindication for Cisplatin


Hematology Cancer:


Acute Myeloid Leukemia (AML):

Chronic Lymphocytic Leukemia (CLL):

  • Alliance A041702: A Randomized Phase III Study of Ibrutinib + Obinutuzumab vs. Ibrutinib + Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) 
  • ECOG-ACRIN EA9161: A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab vs. Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Mantle Cell:

  • PrE0404: A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
  • ECOG-ACRIN EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
  • UW16086: Bendamustine + Obinutuzumab Induction Chemoimmunotherapy with Risk-Adapted obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell lymphoma

Non-Hodgkins Lymphoma:

  • ACE-LY-003: Study of Acalabrutinib alone or in Combination Therapy in Subjects With B-Cell Non-Hodgkins Lymphoma

Follicular Lymphoma:

  • PCYC-1141-CA: A Mulitcenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab vs. Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
Multiple Myeloma:
  • ECOG E1A11: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
  • Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy.
Myelodysplastic Syndrome (MDS)/Anemia:
  • ConnectMDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Registry
  • Exact Science 2018-02: Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Hematologic Malignancies

Lung Cancer

Non-Small Cell Lung Cancer (NSCLC):

  • Alliance A081105: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
  • Alliance A151216: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery
  • ECOG E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • ECOG EA5142: Adjuvant Nivolumab in Resected Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
  • S1900 (LUNGMAP): A Master Protocol to Evaluate Biomarker Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
  • ECOG-ACRIN EA5163: A Randomized, Phase III Study of First Line Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Post progression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis
  • NRG-LU003: A Biomarker-Driven Protocol for Previously Treated AKL-Positive Non Squamous NSCLC Patients: The NCI-AK Protocol


  • Exact Science 2016-11: Blood Sample Collection in Subjects Participating in Lung Cancer Screening Program

Skin Cancer

  • ECOG EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilumumab plus Sargramstim versus Nivolumab plus Ipilumumab in Patients with Unresectable Stage III or Stage IV Melanoma.
  • SWOG S1320: A Randomized, Phase II Trial of INtermittent vs. Continuous Dosing of Dabrafenib and Trametinib in BRAF Mutant Melanoma
  • SWOG S1801: A Phase II Randomized Study of Adjuvant vs Neo-Adjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma


  • Exact Science 2018-03: Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Melanoma

Neurological/Brain Cancer

Glioblastoma Multiforme (GBM):

  • ECOG EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma.

Low Grade Glioma:

  • NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma


  • Alliance A071401- Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
  • NRG-BN003 - Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Symptom Management:

  • EAP-001: An Open-Label, Expanded Access Protocol for Firdapse Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS) and Downbeat Nystagmus.


  • Alliance A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib vs. Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)